Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Bullboard Posts
Comment by mkprovoson Jun 17, 2010 2:34pm
545 Views
Post# 17198932

RE: RE: RE: RE: RE: timeline

RE: RE: RE: RE: RE: timeline

Wow, that was enlightening.

I have made plenty of money off trading stock, don't worry about me.  I am just sick of the fear controlling the markets right now and the shorters getting it all.  Kind of rediculous.  But I have some good short positions as well so la- dee - da.

Sorry,I didn't know that adding possibly before a stupid statement made it null and void....? Sorry I miss understood that societal understanding...

Reuters said it failed to show statistical significance versus the placebo.  That is not the concern.  We do not have the data of what dosages they are comparing to and this is only NHISS score.  We do not have the info yet to know what was compared and how. So that comment from Reuters is a very small one, which is the same reality of what we all know.  FOR NHISS the placebo did better than SCT's drug.  That is knwon by all, big deal.  lets get the result report and see what comes out. 

Reuters did not mention that SCT's drug showed statistical significance to doing nothing at all in the general population.  And your arguments seem to leave out these good points for some reason?? Care to elaborate? Basher?

Here are some things to know based on facts not "Possibly's"
1) Placebo did better than SCT drug
2) Placebo and SCT drug both were statistically significant versus no treatment
3) Phase II only looks at dosage safety and efficacy (does not care about placebo).
4) In phase II SCT drug was safe and proved efficacy.  Ignore the placebo effect because it is not necessary for approval to move to phase III.  It is a good to know though so they can control it out for Phase III.  

As for Dr. Moore's Pay, I am calling BS to them making more than private inductry.  I know they took a pay cut in the last couple of years to reduce expenses.  I do not have my reports that get mailed to me right now, but I remember the employees being quite resonably paid, nothing extravigant. 

If you are not bashing, please post the compensation you think is too high and let us all judge on our own instead of taking your word that it is way too high.  I seem to recall it being reasonable.   


 



Bullboard Posts